Illumina Inc. Stock Underperforms Friday When Compared To Competitors

MacroGenics Inc

Change company Symbol lookup

Select an option...

MGNX MacroGenics Inc

CBZ CBIZ Inc

PSEC Prospect Capital Corp

SPEC Spectralcast Inc

RC Ready Capital Corp

GNK Genco Shipping & Trading Ltd

NVOS Novo Integrated Sciences Inc

PDRDF Pernod Ricard SA

RKDA Arcadia Biosciences Inc

BBVA Banco Bilbao Vizcaya Argentaria SA

Health Care : Biotechnology | Small Cap Value

Company profile

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

Illumina Inc. Stock Underperforms Friday When Compared To Competitors

5:01 pm ET January 7, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Illumina Inc. (ILMN) slipped 2.26% to $370.36 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.41% to 4,677.03 and Dow Jones Industrial Average falling 0.01% to 36,231.66. Illumina Inc. closed $185.41 below its 52-week high ($555.77), which the company achieved on February 12th.

The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Thermo Fisher Scientific Inc. (TMO) fell 2.15% to $607.07, Danaher Corp. (DHR) fell 2.71% to $295.67, and Agilent Technologies Inc. (A) fell 2.66% to $145.15. Trading volume (1.0 M) eclipsed its 50-day average volume of 908,392.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 7, 2022.

-MarketWatch Automation

(END) Dow Jones Newswires

January 07, 2022 17:01 ET (22:01 GMT)